$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”

<p>Could GLP-1 medications eventually cost just $40 to $50 per month? Hims &amp; Hers CEO Andrew Dudum thinks so, and if he’s right, it could completely change access to obesity treatment in America.</p><p><br></p><p>But getting there may depend on something most patients have never heard of: the global peptide manufacturing supply chain.</p><p><br></p><p>In this episode of The Weekly Dose from On The Pen, Dave Knapp, Man on the Mounjaro, breaks down one of the biggest weeks in GLP-1 and obesity medicine news, including the surprising role of Chinese pharmaceutical manufacturer WuXi AppTec, which Bloomberg described as having a “GLP-1 chokehold” while U.S. policymakers wrestle with reducing America’s dependence on Chinese biotechnology.</p><p><br></p><p>We also dig into one of the strangest GLP-1 stories of the year. Amylyx Pharmaceuticals just reported positive Phase 3 results for avexitide, a GLP-1 receptor antagonist, meaning it actually BLOCKS GLP-1. The drug reduced serious hypoglycemic events by 55% in patients with post-bariatric hypoglycemia, a debilitating condition that can occur after gastric bypass surgery.</p><p><br></p><p>Then we get personal.</p><p><br></p><p>Online personality Clavicular recently described becoming apathetic while taking a high dose of retatrutide, renewing the conversation around GLP-1 medications, anhedonia, emotional blunting, dopamine and reward signaling. Dave has firsthand experience with anhedonia during GLP-1 treatment and previously discussed that experience as part of coverage on the Today Show.</p><p><br></p><p>At what point does turning down food noise start turning down everything else?</p><p><br></p><p>We also examine Serena Williams’ return to professional tennis while openly using Zepbound (tirzepatide) and the growing debate over whether GLP-1 medications could ever be considered performance-enhancing drugs in professional sports.</p><p><br></p><p>Plus, new research suggests GLP-1 medications and significant weight loss may improve testosterone levels and fertility markers in men with obesity-related low testosterone, raising important questions about metabolic health, hypogonadism and when testosterone replacement therapy may or may not be appropriate.</p><p><br></p><p>In this episode:</p><p><br></p><p>💉 Could Ozempic, Wegovy, Mounjaro and Zepbound eventually cost $40 to $50 per month?</p><p><br></p><p>🇨🇳 Why WuXi AppTec and China matter to the global GLP-1 supply chain</p><p><br></p><p>💰 How manufacturing capacity could determine future GLP-1 prices</p><p><br></p><p>🧬 Amylyx avexitide Phase 3 results and the “anti-GLP-1”</p><p><br></p><p>🩸 Post-bariatric hypoglycemia after gastric bypass surgery</p><p><br></p><p>🧠 Retatrutide, anhedonia, apathy and emotional blunting</p><p><br></p><p>⚖️ Why anecdotes about GLP-1 side effects still need scientific context</p><p><br></p><p>🎾 Serena Williams, Zepbound and the performance-enhancing drug debate</p><p><br></p><p>💪 GLP-1 medications, weight loss and testosterone in men</p><p><br></p><p>🧬 Obesity, metabolic health, fertility and hypogonadism</p><p><br></p><p>The goal here isn’t to cheerlead GLP-1 medications or scare patients away from them. It’s to understand what the headlines actually mean so patients can have better conversations with their healthcare providers.</p><p><br></p><p>If GLP-1 medications were available for $40 to $50 cash per month without insurance, would that change your ability to stay on treatment? Let me know in the comments.</p><p><br></p><p>And if you’ve experienced anhedonia or emotional flattening while taking a GLP-1 medication, particularly after increasing your dose, I’d be interested in hearing about your experience as well.</p><p><br></p><p>The Weekly Dose is shot live in the Bask Health Studio. Learn more at bask.health</p><p><br></p><p>Thanks to VoaFit and the MyLevel app for sponsoring the podcast. Learn more at voafit.com/otp</p><p><br></p><p>🔗 Follow On The Pen, find our newsletter, resou